RemeGen Co., Ltd. (OTCMKTS:REGMF) Short Interest Update

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 646,500 shares, a growth of 97.1% from the March 15th total of 328,000 shares. Based on an average daily volume of 83 shares, the short-interest ratio is presently 7,789.2 days.

RemeGen Price Performance

REGMF stock opened at $10.95 on Monday. The business’s 50-day moving average is $10.41 and its two-hundred day moving average is $10.50. RemeGen has a 1 year low of $9.81 and a 1 year high of $15.91.

About RemeGen

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.